

Product Update:

adalimumab (Humira[®]) 40mg/0.4mL pre-filled syringe and pre-filled pen
adalimumab (Humira[®]) 40mg/0.8mL vial for paediatric use

SMC No. (1243/17)

AbbVie Ltd

05 May 2017

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

adalimumab (Humira[®]) is accepted for use within NHS Scotland.

Indication under review: treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.

SMC has previously accepted adalimumab for the treatment of active moderate to severe HS (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 13 March 2017.

**Chairman
Scottish Medicines Consortium**